On Monday morning, Lupin’s shares slid 2.01% to ₹2,316.00. The drugmaker, which is part of the Nifty Midcap 150 index, opened the session lower and the decline continued into early trade.
At 9:31 a.m., the stock traded at ₹2,316, down from its previous close. This move reflects a bearish sentiment that has been visible for the stock since August 6, 2026.
In the quarter ending June 2026, Lupin reported revenue of ₹8,276.89 crore, up from ₹6,268.34 crore in the same period last year. Net profit rose to ₹1,417.00 crore from ₹1,221.46 crore, and earnings per share reached ₹30.95, up from ₹26.70.
Year‑to‑date figures also show strong growth. Total revenue climbed to ₹27,958.03 crore in 2026 from ₹16,405.48 crore in 2022. Net profit swung from a loss of ₹1,509.72 crore in 2022 to a profit of ₹5,355.47 crore in 2026, while EPS improved from –₹33.65 to ₹116.75. Return on equity rose from –12.57% to 23.75%.
Operating cash flow surged to ₹7,334 crore in March 2026 from ₹367 crore in March 2022, although investing cash flow stayed negative due to ongoing asset purchases. Net cash flow for March 2026 was ₹2,624 crore. Total assets and liabilities both grew from ₹21,821 crore in 2022 to ₹38,364 crore in 2026.
Lupin has a history of paying dividends. It announced a final dividend of ₹18.00 per share (900%) on May 7, 2026, payable from July 17, 2026. The previous year’s final dividend was ₹12.00 per share (600%) announced on May 14, 2025. Earlier, the company had a 1:1 bonus issue in 2006 and a stock split in 2010.
The company also secured U.S. FDA approval for Sugammadex Injection, announced on July 31, 2026. It released unaudited quarterly results for June 30, 2026, in newspaper ads on August 8, 2026.
Despite the recent positive developments, the current price drop suggests that investors remain cautious. The decline may be temporary as the company’s financial performance and new product launch strengthen its long‑term prospects.